Is Your Cetirizine Safe? FDA Recalls Allergy Medicine Over Possible Ranitidine Contamination

A nationwide recall has been issued for certain cetirizine hydrochloride allergy tablets after the U.S. Food and Drug Administration (FDA) said they may have been contaminated with ranitidine during manufacturing. For many people, that means taking a closer look at the allergy medicine sitting in the medicine cabinet.

The recall also brings back memories of the ranitidine contamination concerns that led to those products being pulled from the U.S. market years ago. Even though this recall affects only a small number of lots, health officials are still urging consumers to check their medication and follow FDA instructions.

Why Was Cetirizine Recalled?

The FDA said the recall was started after manufacturer Unique Pharmaceutical Laboratories, a division of JB Chemicals & Pharmaceuticals Ltd., voluntarily recalled four lots of cetirizine hydrochloride tablets USP 5 mg. According to the agency, the issue came to light when a pharmacy technician noticed unusual red spots and discoloration on some tablets while filling prescriptions. That observation raised concerns that the tablets may have been cross-contaminated with ranitidine during production.

The products were distributed nationwide by Rising Pharma Holdings Inc. The contamination is especially concerning for people who are sensitive to ingredients found in ranitidine, since exposure could lead to serious allergic reactions, including life-threatening anaphylaxis.

This is a voluntary recall, meaning the manufacturer initiated it and the FDA is overseeing the process. Which Cetirizine Products Are Affected? The recall applies only to cetirizine hydrochloride tablets USP 5 mg sold under the Rising Pharma Holdings label.

Consumers should compare the lot number on the bottle with the FDA recall notice to see whether their medication is included. The recalled tablets are generic cetirizine, the same active ingredient used in allergy medicines such as Zyrtec. The FDA has not said that all Zyrtec products are affected.

Why Is Ranitidine Dangerous?

Ranitidine was once commonly sold as a heartburn medicine under brand names such as Zantac. In 2020, the FDA asked that all ranitidine products be removed from the U.S. market after testing showed they could contain N-Nitrosodimethylamine (NDMA). This probable human carcinogen may raise cancer risk with long-term exposure.

This recall is different. The FDA has not said the cetirizine tablets contain NDMA. Instead, the concern is cross-contamination with ranitidine itself, which could trigger severe allergic reactions in people who are sensitive to it.

Should You Stop Taking Cetirizine?

Health experts say there is no need to panic. Only the recalled lots are affected, and no adverse events had been reported to the manufacturer at the time of the recall.

If your medication matches one of the recalled lot numbers:

• Stop using the affected product.
• Contact your pharmacist or healthcare provider.
• Do not stop allergy treatment without talking to your doctor about alternatives.
• If needed, a healthcare professional may recommend another antihistamine.

What Should You Do If You Have the Recalled Medicine?

If you think your medication may be part of the recall:

• Check the lot number on the bottle.
• Follow the manufacturer’s return or disposal instructions.
• Contact the pharmacy where you bought it to ask about a replacement or refund.
• Report any side effects through the FDA’s MedWatch reporting system.

What Symptoms Could the Contamination Cause?

The FDA says people who are allergic or hypersensitive to ingredients found in ranitidine could have severe reactions.

Possible symptoms include:

• Difficulty breathing
• Swelling of the face or throat
• Difficulty swallowing
• Severe itching
• Hives
• Low blood pressure
• Loss of consciousness

These reactions are uncommon, but they can become medical emergencies and need immediate treatment.

This recall follows the FDA’s broader action against ranitidine products in 2019 and 2020, when concerns about NDMA contamination led to the removal of Zantac and generic ranitidine medicines from the U.S. market. Since then, the FDA has increased manufacturing oversight and testing efforts to catch contamination problems before products reach consumers.